Final Program

362 WEDNESDAY • MAY 18
P52
P53
Facilitator:
P54
P55
P56
P57
P58
P59
P60
P61
P62
Assessing Treatment Success with Tiotropium Respimatr by
Combining Responder Rates of Different Patient-Relevant
Outcomes - a Post-Hoc Analysis/A. Anzueto, P.M. Calverley, N.
Metzdorf, A. Mueller, R. Dahl, San Antonio, TX, p.A6822
24-Hour Lung Function Profile of Novel Co-Suspension
Technology Glycopyrrolate/Formoterol Metered Dose Inhaler
Versus Placebo and Spirivar Respimatr, in Patients with
Moderate-To-Very-Severe Chronic Obstructive Pulmonary
Disease/C. Reisner, G. Gottschlich, F. Fakih, A. Koser, J.
Krainson, L. Delacruz, S. Arora, G. Feldman, K. Pudi, S. Siddiqui,
C. Orevillo, A. Maes, Morristown, NJ, p.A6823
N.R. Bhakta, MD, PhD, San Francisco, CA
A Novel Biophysical Model to Investigate Regional and Total
Lung Delivery of QVA149 (IND/GLY) Delivered Via the
Neohalerr Device/A. Kuttler, T. Dimke, Basel, Switzerland,
p.A6824
Comparative Efficacy of Umeclidinium with Other Once-Daily
Long-Acting Muscarinic Antagonists in Moderate-to-Severe
Chronic Obstructive Pulmonary Disease/I. Naya, P. Shah, M.
Vahdati-Bolouri, W. Fahy, Uxbridge, United Kingdom, p.A6825
The Effect of Indacaterol/ Glycopyrronium on Lung Function
and Physical Activity in More Severe COPD - A Posthoc
Subgroup Analysis of the MOVE Study/H. Watz, C. Mailaender,
A.-M. Kirsten, Grosshansdorf, Germany, p.A6826
Pharmacokinetic and Safety Profile of a Novel Co-Suspension
Technology Fixed-Dose Combination of
Budesonide/Glycopyrrolate/Formoterol Delivered by Metered
Dose Inhaler in Healthy Adult Subjects/C. Orevillo, J. Miller, P.
DePetrillo, S. Siddiqui, S. Ballal, C. Reisner, Morristown, NJ,
p.A6827
Pharmacokinetic and Safety Profile of the Novel LAMA/LABA
Co-Suspension Technology Glycopyrrolate/Formoterol
Fumarate Fixed-Dose Combination MDI, in Japanese Healthy
Subjects/C. Orevillo, J. Miller, P. DePetrillo, A. Maes, S. Siddiqui,
C. Reisner, Morristown, NJ, p.A6828
Effect of Organic Cation Transport Inhibition on the
Pharmacokinetics of Glycopyrronium Bromide in Fixed
Combination with Beclomethasone Dipropionate and
Formoterol Fumarate/D. Cuomo, F. Mariotti, G. Ciurlia, L.
Spaccapelo, M. Scuri, A. Muraro, D. Acerbi, Parma, Italy, p.A6829
Pharmacokinetics of a Novel Triple Fixed Dose Combination
Metered Dose Inhaler: Comparison with the Free Combination
and the Single Components/D. Cuomo, F. Mariotti, S. Collarini, A.
Muraro, D. Acerbi, Parma, Italy, p.A6830
Umeclidinium Dose-Response in Patients with Fixed Airflow
Obstruction and Reversibility to Albuterol Irrespective of a
Primary Diagnosis of Asthma or COPD/L. Lee, E. Kerwin, K.
Collison, W. Wu, S. Yang, S. Pascoe, Stevenage, United Kingdom,
p.A6831
Comparative Assessment of Umeclidinium/Vilanterol
(UMEC/VI) Combination Therapy Among Symptomatic Patients
with COPD/E. Huisman, A. Ismaila, I. Naya, A. Karabis, Y.S.
Punekar, Houten, Netherlands, p.A6832
P63
P64
P65
P66
P67
P68
D37
Health-Related Quality of Life Among Patients Who
Experienced Prior COPD-Related Exacerbations: Post Hoc
Analysis of a 52-Week Randomized Placebo-Controlled Trial of
Nebulized Arformoterol Tartrate/J. Donohue, V. Ganapathy, L.
Nelson, X. Zhou, Chapel Hill, NC, p.A6833
Tudorza PRESSAIRr Patient Satisfaction and Preference
Study/J.R. Davis, R.S. Epstein, M. Leone-Perkins, S. Dixit, K.M.
Fox, F. Trudo, Willmington, DE, p.A6834
Impact of Adherence to ICS/LABA Therapy on the Rate of
COPD Exacerbations/J.R. Davis, F. Trudo, B. Wu, O. Tunceli, J.
Horton, D.M. Kern, K.M. Fox, Wilmington, DE, p.A6835
SURF-COPD: The Recording of Cardiovascular Risk in Patients
With Chronic Lung Disease/A. Dudina, S. Lane, M. Butler, M.-T.
Cooney, I. Graham, Dublin, Ireland, p.A6836
COPD Symptom Based Management and Optimize Treatment
Strategy in Japan (The COSMOS-J Trial)/P.W. Jones, M. Kato, K.
Fujimoto, A. Kobayashi, T. Hayamizu, H. Hitosugi, M. James, G.
Hagan, T. Betsuyaku, Brentford, United Kingdom, p.A7906
A Randomized Trial of Once-Daily Fluticasone
Furoate/Vilanterol 100/25 Versus Vilanterol 25 to Evaluate the
Contribution on Lung Function of Fluticasone Furoate in the
Combination in Subjects with COPD/T. Siler, A. Nagai, C.A.
Scott-Wilson, D.A. Midwinter, C. Crim, St Charles, MO, p.A7907
THEMATIC POSTER SESSION
COPD: DEVELOPMENTAL THERAPEUTICS
9:00 a.m. - 3:30 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area A, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
Facilitator:
P70
P71
P72
R.C. Balkissoon, MD, Denver, CO
Assessment of the Effect of Pulsed Inhaled Nitric Oxide in
COPD Patients with Pulmonary Hypertension using Functional
Respiratory Imaging (FRI)/F. Ferreira, B. Hajian, W. Vos, J. De
Backer, C. Van Holsbeke, L. Nuyttens, D. Quinn, W. De Backer,
Kontich, Belgium, p.A6837
A Phase I, Randomised, Double Blind, Placebo Controlled,
Study to Assess the Safety, Tolerability and Pharmacokinetics
of Multiple Inhaled Doses of RPL554 Administered by
Nebuliser to Healthy Male Subjects and Stable COPD
Patients/D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman,
Manchester, United Kingdom, p.A6838
A Phase I, Randomised, Double Blind, Placebo Controlled,
Study to Assess the Safety, Tolerability and Pharmacokinetics
of Single Inhaled Doses of the Dual Phosphodiesterase 3/4
(PDE3/4) Inhibitor RPL554 Administered by Nebuliser to
Healthy Male Subjects/D. Singh, K.H. Abbott-Banner, F. Reid, K.
Newman, Manchester, United Kingdom, p.A6839
ATS 2016 • San Francisco